ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2648

Randomized Placebo-Controlled Trial of Local Steroid Injection for Moderately Severe Carpal Tunnel Syndrome

Isam Atroshi1, Magnus Flondell2 and Manfred Hofer3, 1Department of Orthopedics Hässleholm-Kristianstad, Lund University, Hässleholm, Sweden, 2Department of Hand Surgery, Lund University, Malmö, Sweden, 3Physiotherapy, Kristianstad Hospital, Kristianstad, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Carpal tunnel syndrome and corticosteroids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Orthopedics, Low Back Pain, and Rehabilitation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Patients with idiopathic carpal tunnel syndrome (CTS) are commonly treated with local steroid injection but there is currently no evidence from placebo-controlled trials supporting efficacy beyond 1 month.

Methods:

We conducted a randomized triple-blind placebo-controlled trial of first-time steroid injection into the carpal tunnel in patients with moderately severe CTS. Patients aged 18 to 70 years with primary idiopathic CTS, no severe sensory loss or muscle atrophy, and no previous steroid injection for CTS were randomized to 1 of 3 groups (37 patients in each): 80 mg Methylprednisolone, 40 mg Methylprednisolone, or saline (each also containing 10 mg Lidocaine). Patient-reported outcomes (CTS symptom severity scale, QuickDASH, SF-36 bodily pain, and SF-6D) were obtained and physical examination by a blinded assessor was performed at baseline and at 10, 24 and 52 weeks after injection. The primary end points were change in CTS symptom severity score at 10 weeks and rate of surgery at 52 weeks. Data from all patients were analyzed.

Results:

During 1 year after injection surgery was carried out on 27 patients (73%) in the 80 mg Methylprednisolone group, on 30 patients (81%) in the 40 mg Methylprednisoline group, and on 34 patients (92%) in the placebo group. Patients who received placebo were significantly more likely to have surgery during 1 year after injection than patients who received Methylprednisolone; adjusted hazard ratio 2.0 (95% confidence interval 1.3-3.2, P<0.01). The change in the CTS symptom severity score from baseline to 10 weeks was significantly larger in both Methylprednisolone groups than in the placebo group. 

Conclusion:

In patients with moderately severe carpal tunnel syndrome first-time steroid injection into the carpal tunnel has a significant benefit in relieving symptoms up to 10 weeks and in reducing the need for surgery up to 1 year after treatment.


Disclosure:

I. Atroshi,
None;

M. Flondell,
None;

M. Hofer,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/randomized-placebo-controlled-trial-of-local-steroid-injection-for-moderately-severe-carpal-tunnel-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology